Lanean...
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase active site. While effective at blocking the catalytic ac...
Gorde:
| Argitaratua izan da: | eLife |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
eLife Sciences Publications, Ltd
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7834017/ https://ncbi.nlm.nih.gov/pubmed/33226337 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.60470 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|